MET and cancer: Importantly, among the corresponding fusions, 13 were in‐frame with KD‐intact MET as the 3' partner, involving 5' partners actionable targets such as protein kinase A (PRKAR1A),40 targets with ongoing drug development such as Tousled‐like kinase 2 (TLK2),41 proposed prognostic biomarkers such as LRIG42 and DOCK4,43 and genes with preclinical evidence of cancer‐associated activity such as DIXDC144 and YEATS2 .45